Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs REMEVi

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, REMEVi a 84. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$99/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

REMEVi

#32 · Grade B+ · Good Value

Est. first month

$219/mo (all doses, compounded)

Save ~84% vs brand-name
Get this deal Full REMEVi review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 84 an est. $99/mo first month, with no teaser step-up baked in. REMEVi isn't out of it: Shoppers who want spanish-speaking patients wanting bilingual, LegitScript-certified compounded GLP-1.

CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxREMEVi
Value Score93 (A+)84 (B+)
Est. first month$99/mo$219/mo (all doses, compounded)
Save vs brand-name~89%~84%
Semaglutide$99/mo$219/mo (all doses, compounded)
Tirzepatide$149/mo$319/mo (all doses, compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
68
CoreAge Rx: 88. REMEVi: 68.
98
No Teaser-Rate Bait
90
CoreAge Rx: 98. REMEVi: 90.
98
Nationwide Availability
96
CoreAge Rx: 98. REMEVi: 96.
95
Both Molecules
98
CoreAge Rx: 95. REMEVi: 98.
95
Easy Cancellation
95
CoreAge Rx: 95. REMEVi: 95.
84
Reputation
87
CoreAge Rx: 84. REMEVi: 87.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

REMEVi

REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

Why it's a deal

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

The fine print

  • The flat rate is one of the highest entry prices in this ranking; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
Get the CoreAge Rx deal Get the REMEVi deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to REMEVi.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.